Avalo Therapeutics AVTX Income Statement (2014-2026)

NASDAQ AVTX
$19.21 +0.21 (+1.11%)
As of: Sep 4, 2026 · 12:50 PM EDT
Reported Financials

Avalo Therapeutics Quarterly Income Statement

Periods 48 quarters
Latest Jun 2026

Avalo Therapeutics reported net income of -$36.94M for the quarter ended Jun 2026. This income statement covers 48 quarters of results from Sep 2014 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Income Statement Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Shares Outstanding (Entity)Shares Outstanding (Entity.)
0.04M0.04M0.04M0.04M0.04M0.04M0.06M0.06M0.20M0.28M0.86M1.03M5.55M4.43M10.83M10.84M14.00M13.40M43.60M
Revenue & cost
Revenue
1.35M0.22M1.17M1.03M14.95M0.90M0.47M0.64M0.24M0.57M0.25M0.19M0.06M
Gross Profit
0.44M-0.20M0.45M-0.53M14.42M0.28M-0.08M-0.07M-0.01M0.79M-0.08M-0.34M-0.47M
Operating items
Amortization - Intangibles
0.43M0.27M0.04M
Research & DevelopmentR&D
10.55M11.51M9.58M8.51M7.04M6.17M6.01M4.66M1.25M1.87M2.12M4.60M9.54M8.18M9.12M14.07M13.62M13.27M14.05M23.42M
Selling, General & AdministrativeSG&A
5.93M5.98M11.68M2.78M3.28M2.96M2.71M2.43M2.49M2.68M3.19M4.53M4.29M5.23M5.55M5.24M5.58M6.53M6.85M8.10M
Other Operating ExpensesOther Opex
1.34M0.69M0.76M1.57M0.53M0.62M0.55M0.71M0.25M3.69M27.46M0.45M-0.71M0.09M
Operating ExpensesOpex
17.81M18.18M22.03M12.86M10.85M9.75M9.27M7.79M3.99M8.23M32.77M9.57M13.11M13.50M14.67M19.32M19.20M19.80M20.90M31.52M
Operating IncomeOp. Inc
-16.46M-17.96M-20.85M-11.83M4.09M-8.86M-8.79M-7.15M-3.75M-7.66M-32.77M-9.57M-12.86M-13.31M-14.67M-19.32M-19.20M-19.74M-20.90M-31.52M
EBIT
-16.46M-17.96M-20.85M-11.83M4.09M-8.86M-8.79M-7.15M-3.75M-7.66M-32.77M-9.57M-12.86M-13.31M-14.67M-19.32M-19.20M-19.74M-20.90M-31.52M
Non-operating items
Non Operating Interest Expenses
Non Operating Investment Income
Interest & Investment IncomeInt & Inv Inc
-0.98M-1.18M-1.17M-1.15M-0.90M-0.95M-0.95M-1.00M-1.55M0.08M0.10M1.04M0.96M1.21M1.15M1.10M1.12M0.98M0.80M2.76M
Other Non Operating IncomeOther Non Op Inc.
-0.01M-0.02M-0.18M-0.04M0.10M0.08M-0.12M-0.01M-0.01M-0.00M
Non Operating IncomeNon Op. Inc.
-1.00M-1.18M-1.19M-1.15M-0.90M-0.95M-1.16M-1.04M-1.47M-0.52M-88.52M108.05M35.88M-21.91M1.53M-1.43M-11.42M6.15M1.28M-4.82M
Net income details
EBT
-17.46M-19.15M-22.04M-12.98M3.20M-9.80M-9.95M-8.19M-5.22M-8.18M-121.28M98.47M23.02M-35.23M-13.14M-20.75M-30.61M-13.59M-19.62M-36.34M
Tax ProvisionsTaxes
0.01M0.00M0.01M0.01M0.01M0.01M0.01M0.01M0.01M-0.01M0.01M0.01M-0.01M0.11M0.01M0.02M0.01M0.13M0.01M0.02M
Profit After TaxPAT
-17.47M-19.16M-22.05M-12.99M3.19M-9.81M-9.96M-8.19M-5.23M-8.17M-121.29M98.46M23.04M-35.34M-13.15M-20.80M-30.62M-13.76M-19.70M-36.94M
Income from Continuing OperationsIncome (Continuing)
-17.47M-19.15M-22.05M-12.99M3.19M-9.81M-9.96M-8.19M-5.23M-8.17M-121.29M98.46M23.04M-35.34M-13.15M-20.77M-30.62M-13.72M-19.63M-36.36M
Income from Discontinued OperationsIncome (Discontinued)
0.08M-0.07M
Consolidated Net IncomeConsol Net Inc.
-17.39M-19.22M-22.05M-12.99M3.19M-9.81M-9.96M-8.19M-5.23M-8.17M-121.29M98.46M23.04M-35.34M-13.15M-20.77M-30.62M-13.72M-19.63M-36.36M
Income towards Parent CompanyParent Net Inc
-17.39M-19.22M-22.05M-12.99M3.19M-9.81M-9.96M-8.19M-5.23M-8.17M-121.29M98.46M23.04M-35.34M-13.15M-20.77M-30.62M-13.72M-19.63M-36.36M
Net Income towards Common StockholdersNet Income
-17.39M-19.22M-22.05M-12.99M3.19M-9.81M-9.96M-8.19M-5.23M-8.17M-121.29M98.46M23.04M-35.34M-13.15M-20.77M-30.62M-13.72M-19.63M-36.36M
Additional items
EPS (Basic)
-498.14-553.60-562.58-331.2881.32-250.10-203.65-140.62-26.81-29.41-141.1495.214.15-7.98-1.25-1.92-2.19-1.02-1.46-0.83
EPS (Diluted)
-498.15-551.61-562.58-331.2881.31-250.10-203.65-140.62-26.81-29.41-141.1412.872.14-4.71-1.25-1.92-2.19-1.02-0.98-1.81
Shares Outstanding
0.03M0.03M0.04M0.04M0.04M0.04M0.05M0.06M0.20M0.28M0.86M1.03M5.55M4.43M10.51M10.83M14.00M13.40M13.40M43.60M
Shares Outstanding (Diluted)Shares Outstanding (Dil.)
0.03M0.03M0.04M0.04M0.04M0.04M0.05M0.06M0.20M0.28M0.86M7.65M10.78M7.50M10.51M10.83M14.00M13.40M20.11M20.11M
EBITDA
-16.46M-17.96M-20.85M-11.83M4.09M-8.86M-8.79M-7.15M-3.75M-7.66M-32.77M-9.57M-12.86M-13.31M-14.67M-19.32M-19.20M-19.74M-20.90M-31.52M
Interest ExpensesInt Expense
Tax Rate
-0.05-0.02-0.04-0.040.16-0.08-0.08-0.09-0.150.11-0.010.01-0.06-0.32-0.06-0.08-0.04-0.96-0.06-0.05